Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Rhythm Biosciences Ltd. ( (AU:RHY) ) has issued an update.
Rhythm Biosciences Ltd has initiated the commercialization of its ColoSTAT® test, a blood-based diagnostic tool for colorectal cancer, following an updated ISO15189:2022 accreditation. This marks a significant milestone as ColoSTAT® addresses the unmet clinical need for patients where stool-based testing is unsuitable or not preferred. The test will be rolled out through Rhythm’s certified laboratory in Melbourne, with immediate domestic market activities. The company plans to conduct a variation to scope assessment with the National Association of Testing Authorities in January 2026, which would further establish ColoSTAT® as an accredited laboratory service, enhancing clinician confidence and commercial scalability.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd (ASX: RHY) is an Australian medical diagnostics company focused on developing simple, affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, Australia, the company aims to improve patient outcomes and reduce the global cancer burden by partnering with global entities for the commercialization and distribution of its solutions.
Average Trading Volume: 340,927
Technical Sentiment Signal: Sell
Current Market Cap: A$26.29M
See more data about RHY stock on TipRanks’ Stock Analysis page.